Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMA105 Injection for overweight or obesity (Phase Ib/II)
CTR20221601Phase 2Active
- Sponsor
- Gmax Biopharm
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of glutazumab in Overweight, obesity, sponsored by Gmax Biopharm. Started Sep 2022; status: active.
02
Drugs
glutazumab
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20221601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221601.